Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Novel Osteobiologic Proteins for Treatment of Osteoporosis, Rheumatoid and Neurologic Diseases

Posted Jun 02 2010 5:00pm

Description of Invention:
In an effort to find effective strategies for treatment of body tissue and structural damage as the result of trauma, cancer and other diseases, scientists at the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) have identified proteins and associated pathways instrumental in replacing or regenerating damaged tissue. The identified proteins include Cartilage-Derived Morphogenetic Proteins (CDMP), Bone Morphogenetic Proteins (BMPs) and a tissue fate modifying FRZB Protein. Each has unique activities likely to be useful as stand alone agents or in construction of engineered tissues.

CDMPs appear helpful in the healing of bone and joint surface lesions, and also for the repair or reconstruction of cartilaginous tissues, tendons and ligaments. BMP antagonists will be useful in the study of stem cell differentiation. FRZB Protein, a tissue fate modifying secretable antagonist of Wnt signaling, is involved in the formation of cartilage, bone, neural and muscle tissue.

Applications:
  • rheumatic diseases of the bone
  • osteoporosis and osteoarthritis
  • wound healing
  • neurodegenerative disorders
  • growth and repair of musculoskeletal tissues
  • tissue engineering
Cartilage-Derived Morphogenetic Proteins (HHS Reference No. E-138-1994/0):
  • useful in the therapeutic induction, repair, and maintenance of skeletal tissues and cartilage growth.
  • polynucleotides encoding these proteins are effective diagnostic reagents for detecting genetic abnormalities associated with poor skeletal development.
Tissue Fate Modifying FRZB Protein (HHS Reference Nos. E-127-1995/0 /1 /2):
  • involved in the formation of cartilage, bone, neural and muscle tissue.
  • regenerative agent to treat degenerative disorders, (i.e., Huntington's, Alzheimer's or spinal cord injuries), myodegenerative disorders (i.e., muscular dystrophy, myasthenia gravis or myotonic myopathies) and osteodegenerative disorders (i.e., osteoporosis or osteoarthritis)
  • selectively blocks diseases associated with Wnt family of signaling molecules including neoplasias.
Bone Morphogenetic Protein Variants (HHS Reference No. E-196-2004/0):
  • promote repair of menisci, cruciate and collateral ligaments of the knee, and rotator cuff or other tendons and/or ligaments.
  • induce the proliferation and differentiation of progenitor cells into functional bone, cartilage, tendon, or ligament tissue.


Advantages:
Osteobiologics, such as BMPs, have the ability to stimulate musculo-skeletal repair instead of using donated human tissue allografts and synthetic materials.

Inventors:
Frank P Luyten (NIDCR)
Malcolm C Moos (FDA)


Patent Status:
HHS, Reference No. E-138-1994/0
US, , Patent No. 7,148,036, Issued 12 Dec 2006
US, , Patent No. 7,220,558, Issued 22 May 2007
US, , Patent No. 6,884,871, Issued 26 Apr 2005
US, , Patent No. 6,924,367, Issued 02 Aug 2005
US, , Patent No. 7,563,596, Issued 21 Jul 2009
US, , Patent No. 7,049,291, Issued 23 May 2006
US, Application No. 11/916,990 filed 08 Jul 2006


Relevant Publication:
  1. K Lin, S Wang, MA Julius, J Kitajewski, M Moos Jr., FP Luyten. The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for the modulation of Wnt signaling. Proc Natl Acad Sci. USA 1997 Oct 14;94(21):11196-11200. [ PubMed abs ]
  2. B Hoang, M Moos Jr, S Vukicevic, FP Luyten. Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggests a role in skeletal morphogenesis. J Biol Chem. 1996 Oct 18;271(42):26131-26137. [ PubMed abs ]


Licensing Status:
Available for licensing.


Portfolios:
Cancer
Cancer - Therapeutics
Gene Based Therapies
Gene Based Therapies - Therapeutics
Internal Medicine
Internal Medicine - Therapeutics
Miscellaneous
Central Nervous System - Therapeutics
Rare Diseases



For Additional Information Please Contact:
Surekha Vathyam Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: vathyams@mail.nih.gov
Phone: 301-435-4076
Fax: 301-402-0220


Ref No: 1981

Updated: 06/2010

Post a comment
Write a comment: